SEMAGLUTIDE IS MORE EFFECTIVE FOR WEIGHT LOSS IN WOMEN COMPARED TO MEN, BUT BOTH BENEFIT IF DIAGNOSED WITH HEART FAILURE.
SEMAGLUTIDE IS MORE EFFECTIVE FOR WEIGHT LOSS IN WOMEN COMPARED TO MEN, BUT BOTH BENEFIT IF DIAGNOSED WITH HEART FAILURE. Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced more significant weight loss and the same symptom benefits compared with men, according to research presented today by Dr. Subodh Verma (St. Michael's Hospital, University of Toronto) at the American Diabetes Association's 2024 Scientific Sessions and published in the Journal of the American College of Cardiology ( JACC ). This secondary analysis of the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program reveals that semaglutide provides benefits for men and women that do not track directly with weight loss, suggesting the drug may also have weight-loss-independent effects on the ...